iSpecimen Inc
iSpecimen Inc. operates marketplace that provides biospecimens to life science researchers worldwide. The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. Its marketplace offers human biospecim… Read more
iSpecimen Inc (ISPC) - Net Assets
Latest net assets as of September 2025: $3.07 Million USD
Based on the latest financial reports, iSpecimen Inc (ISPC) has net assets worth $3.07 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($9.00 Million) and total liabilities ($5.92 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $3.07 Million |
| % of Total Assets | 34.15% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 14.03 |
iSpecimen Inc - Net Assets Trend (2018–2024)
This chart illustrates how iSpecimen Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for iSpecimen Inc (2018–2024)
The table below shows the annual net assets of iSpecimen Inc from 2018 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $3.31 Million | -66.01% |
| 2023-12-31 | $9.74 Million | -52.04% |
| 2022-12-31 | $20.31 Million | -31.83% |
| 2021-12-31 | $29.79 Million | +209.21% |
| 2020-12-31 | $-27.28 Million | -20.07% |
| 2019-12-31 | $-22.72 Million | -23.31% |
| 2018-12-31 | $-18.42 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to iSpecimen Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 5211616400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $170.00 | 0.01% |
| Other Components | $75.17 Million | 2270.41% |
| Total Equity | $3.31 Million | 100.00% |
iSpecimen Inc Competitors by Market Cap
The table below lists competitors of iSpecimen Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
The Gold Bond Group Ltd
TA:GOLD
|
$2.16 Million |
|
Weed Inc
OTCQB:BUDZ
|
$2.16 Million |
|
MARKET VECTR RETAIL
BE:VEFW
|
$2.16 Million |
|
SCL_S.C.L. MOTOR PART
BK:SCL
|
$2.16 Million |
|
Klimator AB
ST:KLIMAT
|
$2.15 Million |
|
Sixty Six Capital Inc
OTCQB:HYHDF
|
$2.15 Million |
|
CIBOX INTER. NOM. EO -02
F:1YH
|
$2.15 Million |
|
GENMAB - Dusseldorf Stock Exchang
DU:GE9
|
$2.15 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in iSpecimen Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 9,741,077 to 3,311,008, a change of -6,430,069 (-66.0%).
- Net loss of 12,497,805 reduced equity.
- New share issuances of 1,892,856 increased equity.
- Other comprehensive income decreased equity by 840.
- Other factors increased equity by 4,175,720.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-12.50 Million | -377.46% |
| Share Issuances | $1.89 Million | +57.17% |
| Other Comprehensive Income | $-840.00 | -0.03% |
| Other Changes | $4.18 Million | +126.12% |
| Total Change | $- | -66.01% |
Book Value vs Market Value Analysis
This analysis compares iSpecimen Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.05x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $-393.19 | $0.22 | x |
| 2019-12-31 | $-485.39 | $0.22 | x |
| 2020-12-31 | $-582.73 | $0.22 | x |
| 2021-12-31 | $72.91 | $0.22 | x |
| 2022-12-31 | $45.93 | $0.22 | x |
| 2023-12-31 | $21.55 | $0.22 | x |
| 2024-12-31 | $4.66 | $0.22 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently iSpecimen Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -377.46%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -134.51%
- • Asset Turnover: 0.99x
- • Equity Multiplier: 2.82x
- Recent ROE (-377.46%) is below the historical average (-81.71%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 0.00% | -121.67% | 1.09x | 0.00x | $-3.50 Million |
| 2019 | 0.00% | -109.97% | 1.02x | 0.00x | $-2.46 Million |
| 2020 | 0.00% | -56.84% | 1.32x | 0.00x | $-1.92 Million |
| 2021 | -30.08% | -80.48% | 0.31x | 1.20x | $-11.94 Million |
| 2022 | -50.45% | -98.50% | 0.42x | 1.21x | $-12.28 Million |
| 2023 | -113.95% | -111.80% | 0.63x | 1.62x | $-12.07 Million |
| 2024 | -377.46% | -134.51% | 0.99x | 2.82x | $-12.83 Million |
Industry Comparison
This section compares iSpecimen Inc's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $914,015,556
- Average return on equity (ROE) among peers: -22.24%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| iSpecimen Inc (ISPC) | $3.07 Million | 0.00% | 1.93x | $2.16 Million |
| Agilent Technologies Inc (A) | $4.08 Billion | 3.46% | 0.65x | $31.80 Billion |
| Amer Bio Medica (ABMC) | $3.38 Million | -26.64% | 1.08x | $3.55K |
| ADCNF (ADCNF) | $1.77 Billion | 2.65% | 1.64x | $172.01 Million |
| Advanced Biomed Inc. Common Stock (ADVB) | $3.48 Billion | 0.00% | 0.87x | $1.68 Million |
| ANGLE plc (ANPCF) | $18.44 Million | -77.14% | 0.38x | $34.42 Million |
| SeqLL Inc. (ATLN) | $8.18 Million | -45.26% | 0.31x | $35.63K |
| Avricore Health Inc (AVCRF) | $2.20 Million | -79.50% | 0.04x | $3.22 Million |
| Aspira Womens Health Inc (AWH) | $-11.46 Million | 0.00% | 0.00x | $664.47K |
| Biodesix Inc (BDSX) | $-198.03 Million | 0.00% | 0.00x | $50.38 Million |
| bioAffinity Technologies, Inc. (BIAF) | $-15.79 Million | 0.00% | 0.00x | $5.08 Million |